Clinical Trials Browser

Phase 2/3 × toripalimab × Head & Neck × Clear all

NCT05125055 2023-11-22

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck